Table 3.
Food and Drug Administration (FDA)-approved chemotherapy drugs for the treatment of NSCLC. Sources, FDA and National Cancer Institute databases [55,56].
| Generic Name (Brand Name) | Mechanism of Action |
|---|---|
| Carboplatin (Paraplatin®) | Alkylating agent |
| Docetaxel (Taxotere®) | Mitotic inhibitor |
| Doxorubicin Hydrochloride (Adryamycin®, Rubex®) | Topoisomerase inhibitor |
| Gemcitabine Hydrochloride (Gemzar®) | Antimetabolite |
| Lurtotecan (OSI-211) | Topoisomerase inhibitor |
| Mechlorethamine Hydrochloride (Mustargen®) | Alkylating agent |
| Methotrexate (TrexallTM, Rheumatrex®) | Antimetabolite |
| Paclitaxel (Taxol®) | Mitotic inhibitor |
| Paclitaxel–Albumin-stabilized Nanoparticle Formulation (Abraxane®) | Mitotic inhibitor |
| Pemetrexed Disodium (Alimta®) | Antimetabolite |
| Vinorelbine Tartrate (Navelbine®) | Tubuline-binding agent |